Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25239236 | 0.83 | CYP2C9 (0.44) | OPRM1GRIN2BCYP2C9CYP2C19HTR2B | |
| SCHEMBL21093634 | 0.82 | GRIN2B (0.44) | ALDH1A1L3MBTL1GRIN2BRIPK1CYP2C9 | |
| SCHEMBL7810455 | 0.82 | GRIN2B (0.46) | L3MBTL1GRIN2BCYP2C9CYP2C19HTR2B | |
| SCHEMBL3541508 | 0.79 | L3MBTL1 (0.53) | ALDH1A1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL21494357 | 0.78 | ALDH1A1 (0.49) | ALDH1A1GRIN2BRIPK1CYP2C9CYP2C19 | |
| SCHEMBL26144433 | 0.78 | CYP2C9 (0.43) | ALDH1A1L3MBTL1CYP2C9CYP2C19HTR2B | |
| SCHEMBL26144434 | 0.77 | AKR1C3 (0.51) | ALDH1A1L3MBTL1CYP2C9CYP2C19HTR2B | |
| SCHEMBL4313351 | 0.76 | EPHX2 (0.44) | ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL23467257 | 0.74 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1GRIN2BCYP2C9CYP2C19 | |
| SCHEMBL19612576 | 0.74 | CYP2C9 (0.52) | CYP2C9CYP2C19HTR2BMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885L3MBTL1 4095/4885OPRM1 4855/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885L3MBTL1 4095/4885OPRM1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.